MAS1 and pancreatic neoplasm: Finally, we verified the effects of saMAS1+1982/AD in pancreatic cancer organoids derived from patient tumor specimens from the PaCaOmics cohort (ClinicalTrials.gov registration no. NCT01692873).[16] Consistent with the ovarian and breast cancer models, treatment with saMAS1+1982/AD significantly enhanced MAS1 gene expression (Figure S8, Supporting Information) and reduced the viability of cells in the organoids (Figure 5h).